KLK3 and neoplasm: Patients were treated either with chemotherapy alone or in combination with DCs, and data indicate that 23% more patients showed decline in serum prostate-specific antigen (PSA) levels, a liquid biopsy measure of the tumor progression, in response to the combinatorial autologous DC treatment compared to chemotherapy alone [124,125].